About

Certara provides a broad spectrum of model-based drug development software and consulting services, spanning molecular discovery to clinical development, with a special focus on supporting translational approaches to drug development. Certara was formed by the acquisition and integration of industry leaders Tripos, Simcyp, and Pharsight. Each Certara family brand focuses on a key phase within the drug discovery and development process; combined, they offer a unique set of scientific modeling, analysis, and simulation capabilities that can enable the cross-disciplinary approaches necessary for translational science initiatives.

Certara was formed through several acquisitions:

• 2007 – Tripos
• 2008 – Pharsight
• 2012 – Simcyp

Insight & Approach

In 2006, Tripos’s business faced significant operational challenges, was saddled with excessive debt, and was facing delisting. Vector proactively reached out to management to formulate a turnaround solution, and in 2007, Vector acquired Tripos’ software assets, recapitalized the business, and worked with management to revitalize the product strategy and identify acquisition targets to broaden the company’s product offering.

Vector Value Add

Vector refocused the company’s research and development efforts and executed several add-on acquisitions to create a unique, end-to-end product portfolio focused on “translational medicine."

Results

Through several highly successful add-ons and refocused R&D, the company completed its transformation into an end-to-end provider, doubled revenue, and revitalized bookings growth. The company was subsequently acquired by Arsenal Capital in 2013.